2 Pekeris Street
115 articles about CollPlant
CollPlant, a regenerative medicine company, announced the Company will present at the ThinkEquity Conference on Thursday, May 2, 2019 at 10:00 am ET in the Lotus East room of the Mandarin Oriental Hotel in New York City.
CollPlant Renews Distribution Agreement for Its Soft Tissue Repair Product Vergenix™STR With Arthrex a World Leader in Orthopedics
Distribution in Europe, Middle East, India and Africa for the treatment of tendinopathy
Study Published in Wounds Journal Shows Remarkable Wound Closure Performance With CollPlant's VergenixFG in the Treatment of Chronic Wounds With a 94% Median Wound Area Reduction Within 4-weeks
CollPlant, a regenerative medicine company, announced results from a clinical study conducted with its VergenixFG wound care product.
CollPlant Announces Approval of Its rhCollagen Manufacturing Facility by European Union Notified Body
Facility produces proprietary rhCollagen used for BioInks in 3D bioprinting of organs and for dermal fillers
CollPlant, a regenerative medicine company, announced that Jonathan M.N. Rigby has been appointed as Chairman of the Board of Directors effective immediately.
CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants
Collaboration Combines CollPlant’s Proprietary rhCollagen-based BioInk Technology and United Therapeutics’ Regenerative Medicine and Organ Manufacturing Capabilities
CollPlant (NASDAQ: CLGN), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), today announced that management will be ringing the Nasdaq Stock Market Opening Bell on Thursday, November 8, 2018.
Last trading day on the Tel Aviv Stock Exchange (TASE) on October 29, 2018
CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplant
Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities
CollPlant today announced financial results for the second quarter ended June 30, 2018 and provided an update on the Company's business developments.
CollPlant today announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. LLC.
CollPlant's American Depositary Shares to continue trading on the Nasdaq Capital Market
CollPlant announced the appointment of Dr. Wolfgang Ruttenstorfer to its board of directors, increasing the board to seven members.
CollPlant Receives Research and Development Project Approval From the Israel Innovation Authority to Advance its Collagen-based BioInk for 3D Printing of Tissues and Organs
CollPlant announced that it has received grant approval from the Israel Innovation Authority (IIA)
CollPlant Appoints Professor Shay Soker from Wake Forest Institute for Regenerative Medicine to its Scientific Advisory Board
Appointment of Shay Soker, Professor at the Wake Forest Institute for Regenerative Medicine (WFIRM), to its Scientific Advisory Board.
CollPlant is a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products
CollPlant announced that it has completed the third and final closing of the investment agreement with Alpha Capital Anstalt.
CollPlant announced the appointment of Revital Mandil-Levin, PhD, MBA as Chief Business Development Officer, effective immediately.
CollPlant is a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products.
CollPlant Joins ReMDO's Advanced Biomanufacturing Initiative for Development of a Universal BioInk for 3D Bioprinting of Tissues and Organs
CollPlant announced that it is part of ReMDO's advanced biomanufacturing initiative for the development of a universal BioInk with tunable properties for 3D bioprinting of tissues and organs.